4.6 Review

PARP3 comes to light as a prime target in cancer therapy

Journal

CELL CYCLE
Volume 18, Issue 12, Pages 1295-1301

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/15384101.2019.1617454

Keywords

Poly(ADP-ribose) polymerase 3; EMT; mTORC2; cancer aggressiveness

Categories

Funding

  1. Association pour la Recherche contre le Cancer
  2. Ligue Nationale Contre le Cancer
  3. CNRS
  4. Universite de Strasbourg
  5. Ramon Areces Foundation

Ask authors/readers for more resources

Poly(ADP-ribose) polymerase 3 (PARP3) is the third member of the PARP family that catalyze a post-translational modification of proteins to promote, control or adjust numerous cellular events including genome integrity, transcription, differentiation, cell metabolism or cell death. In the late years, PARP3 has been specified for its primary functions in programmed and stress-induced double-strand break repair, chromosomal rearrangements, transcriptional regulation in the zebrafish and mitotic segregation. Still, deciphering the therapeutic value of its inhibition awaits additional investigations. In this review, we discuss the newest advancements on the specific functions of PARP3 in cancer aggressiveness exemplifying the relevance of its selective inhibition for cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available